Steven A. Rosenberg, M.D., Ph.D.
Dr. Rosenberg pioneered the development of effective immunotherapies and gene therapies for patients with advanced cancers. His studies of the adoptive transfer of genetically modified lymphocytes have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T cell receptors that can be exploited to develop new cell transfer immunotherapies for the treatment of cancer patients.
As Chief, Dr. Rosenberg also oversees the Branch’s extensive clinical program aimed at translating scientific advances into effective immunotherapies for patients with cancer.
1) cancer immunotherapy, 2) tumor-infiltrating lymphocytes, 3) cancer antigens,
4) T cell receptors, 5) metastatic melanoma, 6) gene therapy
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 3-3940
Bethesda, MD 20892-1201
Ph: 240-858-3080
SAR@nih.gov
-
A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0143Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - RecruitingNCI Protocol ID NCI-18-C-0049Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Open - RecruitingNCI Protocol ID NCI-14-C-0052Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY-ESO-1 Murine TCR-Gene Engineered Lymphocytes
Open - RecruitingNCI Protocol ID NCI-13-C-0214Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Open - RecruitingNCI Protocol ID NCI-10-C-0166Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Evaluation for NCI Surgery Branch Clinical Research Protocols
Open - RecruitingNCI Protocol ID NCI-99-C-0128Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505
Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
Selected Key Publications
- Nat Immunol. 18(3): 255-262, 2017. [ Journal Article ]
- N Engl J Med. 375(23): 2255-2262, 2016. [ Journal Article ]
- Science. 344: 641-5, 2014. [ Journal Article ]
- Nat Med. 19: 747-752, 2013. [ Journal Article ]
- Clin Cancer Res. 17: 4550-4557, 2011. [ Journal Article ]
Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
| Name | Position |
|---|---|
| Ellen Bodurian R.N., B.S.N. | Research Nurse |
| Colleen E. Buckley R.N. | Research Nurse Specialist |
| Praveen Chatani M.D. | Clinical Fellow |
| Xuemei (Sherry) Chen R.N. | Research Nurse |
| Melissa A. Corbitt | IT Specialist |
| David N. Danforth Jr., M.S., M.D. | Staff Clinician |
| Monica Epstein R.N., B.S.N., O.C.N. | Research Nurse Specialist |
| John Fisher | Quality Assurance Manager (Contr.) |
| Brittany L. Garr-Colon M.P.H., CCRP | Protocol Coordinator (Contr.) |
| Stephanie L. Goff, M.D. | Staff Clinician |
| Meghan Good M.D. | Clinical Fellow |
| Devikala Gurusamy Ph.D. | Scientist (Contr.) |
| Hyuni K. Halas Ph.D. | Scientist (Contr.) |
| Amanda Henning Ph.D. | Postdoctoral Fellow (CRTA) |
| Lutfi Mohaiminul Huq | Postbaccalaureate Fellow (CRTA) |
| Rafiqul Islam Ph.D. | Postdoctoral Fellow (Visiting) |
| Sanghyun Kim Ph.D. | Postdoctoral Fellow (Visiting) |
| Rigel Kishton Ph.D. | Postdoctoral Fellow (CRTA) |
| Vid Leko M.D. | Scientist (Contr.) |
| Noam Levin Ph.D. | Postdoctoral Fellow (Visiting) |
| Mary Link R.N. | Research Nurse Specialist |
| Frank J. Lowery Ph.D. | Research Biologist |
| Yong-Chen (William) Lu Ph.D. | Staff Scientist |
| Takuya Maeda Ph.D. | Postdoctoral Fellow (Visiting) |
| Deepti Jillella Marshall | Patient Care Coordinator (Contr.) |
| Christine T. McGowan R.N. | Research Nurse Specialist |
| Lori S. McIntyre R.N., B.S.N. | Research Nurse Specialist |
| Lien T. Ngo | Technical Laboratory Manager |
| Douglas Palmer Ph.D. | Research Fellow |
| Jennifer A. Pappas M.H.S. | Regulatory Affairs Manager (Contr.) |
| Biman C. Paria Ph.D. | Biologist |
| Sarah C. Ramirez R.N., B.S.N. | Research Nurse Specialist |
| Satyajit Ray Ph.D. | Biologist |
| Richard M. Sherry, M.D. | Staff Clinician |
| Mackenzie Shindorf M.D. | Clinical Fellow |
| Margaret (Peggy) A. Shovlin R.N. | Research Nurse |
| Madusudhanan Sukumar Ph.D. | Staff Scientist |
| Nolan Vale | Postbaccalaureate Fellow (CRTA) |
| Donald E. White | IT Specialist |
| Hui Xu | Biologist |
| Rami Yoseph Ph.D. | Postdoctoral Fellow (Visiting) |
| Jennifer V. Young R.N. | Research Nurse |
| Nikolaos Zacharakis Ph.D. | Research Fellow (Visiting) |
| Xu Zhao M.D., Ph.D. | Developmental Scientist (Contr.) |
| Zhili Zheng | Biologist |
Clinical Trials
-
A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0143Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - RecruitingNCI Protocol ID NCI-18-C-0049Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Open - RecruitingNCI Protocol ID NCI-14-C-0052Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY-ESO-1 Murine TCR-Gene Engineered Lymphocytes
Open - RecruitingNCI Protocol ID NCI-13-C-0214Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Open - RecruitingNCI Protocol ID NCI-10-C-0166Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Evaluation for NCI Surgery Branch Clinical Research Protocols
Open - RecruitingNCI Protocol ID NCI-99-C-0128Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505
Research
Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
Publications
Selected Key Publications
- Nat Immunol. 18(3): 255-262, 2017. [ Journal Article ]
- N Engl J Med. 375(23): 2255-2262, 2016. [ Journal Article ]
- Science. 344: 641-5, 2014. [ Journal Article ]
- Nat Med. 19: 747-752, 2013. [ Journal Article ]
- Clin Cancer Res. 17: 4550-4557, 2011. [ Journal Article ]
Biography
Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg developed the first effective immunotherapies and gene therapies for patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. He was the first to successfully insert foreign genes into humans and his recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas.
Team
| Name | Position |
|---|---|
| Ellen Bodurian R.N., B.S.N. | Research Nurse |
| Colleen E. Buckley R.N. | Research Nurse Specialist |
| Praveen Chatani M.D. | Clinical Fellow |
| Xuemei (Sherry) Chen R.N. | Research Nurse |
| Melissa A. Corbitt | IT Specialist |
| David N. Danforth Jr., M.S., M.D. | Staff Clinician |
| Monica Epstein R.N., B.S.N., O.C.N. | Research Nurse Specialist |
| John Fisher | Quality Assurance Manager (Contr.) |
| Brittany L. Garr-Colon M.P.H., CCRP | Protocol Coordinator (Contr.) |
| Stephanie L. Goff, M.D. | Staff Clinician |
| Meghan Good M.D. | Clinical Fellow |
| Devikala Gurusamy Ph.D. | Scientist (Contr.) |
| Hyuni K. Halas Ph.D. | Scientist (Contr.) |
| Amanda Henning Ph.D. | Postdoctoral Fellow (CRTA) |
| Lutfi Mohaiminul Huq | Postbaccalaureate Fellow (CRTA) |
| Rafiqul Islam Ph.D. | Postdoctoral Fellow (Visiting) |
| Sanghyun Kim Ph.D. | Postdoctoral Fellow (Visiting) |
| Rigel Kishton Ph.D. | Postdoctoral Fellow (CRTA) |
| Vid Leko M.D. | Scientist (Contr.) |
| Noam Levin Ph.D. | Postdoctoral Fellow (Visiting) |
| Mary Link R.N. | Research Nurse Specialist |
| Frank J. Lowery Ph.D. | Research Biologist |
| Yong-Chen (William) Lu Ph.D. | Staff Scientist |
| Takuya Maeda Ph.D. | Postdoctoral Fellow (Visiting) |
| Deepti Jillella Marshall | Patient Care Coordinator (Contr.) |
| Christine T. McGowan R.N. | Research Nurse Specialist |
| Lori S. McIntyre R.N., B.S.N. | Research Nurse Specialist |
| Lien T. Ngo | Technical Laboratory Manager |
| Douglas Palmer Ph.D. | Research Fellow |
| Jennifer A. Pappas M.H.S. | Regulatory Affairs Manager (Contr.) |
| Biman C. Paria Ph.D. | Biologist |
| Sarah C. Ramirez R.N., B.S.N. | Research Nurse Specialist |
| Satyajit Ray Ph.D. | Biologist |
| Richard M. Sherry, M.D. | Staff Clinician |
| Mackenzie Shindorf M.D. | Clinical Fellow |
| Margaret (Peggy) A. Shovlin R.N. | Research Nurse |
| Madusudhanan Sukumar Ph.D. | Staff Scientist |
| Nolan Vale | Postbaccalaureate Fellow (CRTA) |
| Donald E. White | IT Specialist |
| Hui Xu | Biologist |
| Rami Yoseph Ph.D. | Postdoctoral Fellow (Visiting) |
| Jennifer V. Young R.N. | Research Nurse |
| Nikolaos Zacharakis Ph.D. | Research Fellow (Visiting) |
| Xu Zhao M.D., Ph.D. | Developmental Scientist (Contr.) |
| Zhili Zheng | Biologist |
